Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine CSF Concentrations in HIV-1
NCT04079452Phase 3Completed
- Start
- Feb 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoints: Total Doravirine Concentrations in Cerebrospinal Fluid at 4 weeks, Total Doravirine Concentrations in Blood Plasma at 4 weeks and 5 more. Started Feb 2020; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04079452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079452.